Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...
An expert discusses how the phase 3 LUNA 3 trial demonstrated that rilzabrutinib achieved durable platelet responses in 23% ...
Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...
The addition of tiragolumab to Tecentriq and Avastin did not significantly improve progression-free survival in ...
Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free ...
Pembrolizumab (Keytruda) administered before and after surgery reduced the risk of death by 26% vs placebo in patients with early-stage non–small cell lung cancer (NSCLC), according to 5-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback